Literature DB >> 23420096

Pulmonary resection after chemoradiotherapy for advanced non-small cell lung cancer: the impact of presurgical radiation therapy.

Takeshi Shiraishi1, Masafumi Hiratsuka, Jun Yanagisawa, Sou Miyahara, Yasuhiro Yoshida, Yoshifumi Makimoto, Daisuke Hamatake, Shin-ichi Yamashita, Akinori Iwasaki.   

Abstract

PURPOSE: Chemoradiation therapy (CRT) is recommended as standard care for stage III non-small cell lung cancer (NSCLC), but some patients experience local recurrence after the treatment. Surgical resection after CRT involves high surgical risk, but is expected to increase the curability. This study was performed to investigate the impact of presurgical CRT on the postoperative outcome, focusing especially on the effect of radiation therapy.
METHODS: Twenty-six patients with stage III (N2 or T3-4) NSCLC underwent pulmonary resection after CRT. A radiation dose up to 40-70 Gy was given with concurrent chemotherapy. The morbidity, mortality and survival after surgical resection were examined.
RESULTS: Lung resection was performed as lobectomy (73 %) or pneumonectomy (19 %). Postoperative complications occurred in 12 patients (morbidity 46.1 %). The overall 5-year survival of the entire cohort was 69.7 %. The factors associated with favorable long-term survival included a pathological complete response (CR) and mediastinal node negative condition after CRT, and microscopic complete resection.
CONCLUSION: Surgical resection for stage III patients after CRT may provide a survival benefit with acceptable morbidity. The surgical morbidity may be increased by prior radiation therapy, thus, surgeons should be familiar with the available countermeasures to reduce the surgical risk.

Entities:  

Mesh:

Year:  2013        PMID: 23420096     DOI: 10.1007/s00595-013-0520-x

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  23 in total

1.  Comparison of clinical and surgical-pathologic staging of the patients with non-small cell lung carcinoma.

Authors:  Erdogan Cetinkaya; Akif Turna; Pinar Yildiz; Recep Dodurgali; Mehmet Ali Bedirhan; Atilla Gürses; Veysel Yilmaz
Journal:  Eur J Cardiothorac Surg       Date:  2002-12       Impact factor: 4.191

2.  Morbidity and mortality in the surgery arm of EORTC 08941 trial.

Authors:  P Van Schil; J Van Meerbeeck; G Kramer; T Splinter; C Legrand; G Giaccone; C Manegold; N van Zandwijk
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

3.  Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node-negative T3 and T4 non-small cell lung cancer.

Authors:  Benedict D T Daly; Michael I Ebright; Allan J Walkey; Hiran C Fernando; Ken S Zaner; Donna M Morelli; Lisa A Kachnic
Journal:  J Thorac Cardiovasc Surg       Date:  2011-02-01       Impact factor: 5.209

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer.

Authors:  Tae-You Kim; Sung Hyun Yang; Se Hoon Lee; Young-Seok Park; Yung Hyuck Im; Won-Ki Kang; Sung Hwan Ha; Chan Il Park; Dae Seog Heo; Yung-Jue Bang; Noe Kyeong Kim
Journal:  Am J Clin Oncol       Date:  2002-06       Impact factor: 2.339

7.  Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival.

Authors:  Robert James Cerfolio; Ayesha S Bryant; Virginia L Jones; Robert Michael Cerfolio
Journal:  Eur J Cardiothorac Surg       Date:  2009-02-23       Impact factor: 4.191

8.  Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

Authors:  Kathy S Albain; John J Crowley; Andrew T Turrisi; David R Gandara; William B Farrar; Joseph I Clark; Kristie R Beasley; Robert B Livingston
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

9.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.

Authors:  T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; M Tarayre; M J Lacombe-Terrier; J Y Douillard; A Laplanche
Journal:  J Natl Cancer Inst       Date:  1991-03-20       Impact factor: 13.506

10.  Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer.

Authors:  Hiroyasu Yokomise; Masashi Gotoh; Taku Okamoto; Yasumichi Yamamoto; Shinya Ishikawa; Takashi Nakashima; Daiki Masuya; Dage Liu; Cheng-long Huang
Journal:  J Thorac Cardiovasc Surg       Date:  2007-05       Impact factor: 5.209

View more
  2 in total

1.  Extended sleeve lobectomy after induction chemoradiotherapy for non-small cell lung cancer.

Authors:  Shinichi Toyooka; Junichi Soh; Hiromasa Yamamoto; Masaomi Yamane; Shigeru Hattori; Kazuhiko Shien; Kentaroh Miyoshi; Seiichiro Sugimoto; Takahiro Oto; Shinichiro Miyoshi
Journal:  Surg Today       Date:  2014-09-12       Impact factor: 2.549

2.  Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis.

Authors:  Samuel Rosner; Chunnan Liu; Patrick M Forde; Chen Hu
Journal:  JTO Clin Res Rep       Date:  2022-07-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.